Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

0.3300
+0.00702.17%
Post-market: 0.33000.00000.00%19:19 EDT
Volume:330.74K
Turnover:109.63K
Market Cap:10.28M
PE:-0.19
High:0.3500
Open:0.3131
Low:0.3130
Close:0.3230
52wk High:2.88
52wk Low:0.2900
Shares:31.14M
Float Shares:14.58M
Volume Ratio:1.17
T/O Rate:2.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7136
EPS(LYR):-2.7326
ROE:-466.46%
ROA:-65.57%
PB:-3.02
PE(LYR):-0.12

Loading ...

BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy

Reuters
·
May 14

Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K

Benzinga Earnings
·
May 14

Senti Biosciences Holdings Inc: Q1 Net Loss per Share $0.14

THOMSON REUTERS
·
May 14

Press Release: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Dow Jones
·
May 14

Senti Biosciences Holdings Announces Positive FDA Rmat Meeting on Registrational Clinical and Cmc Strategy for Senti-202 in Relapsed/Refractory Aml, Along With Important Efficacy and Durability Updates on the Senti-202 Clinical Program

THOMSON REUTERS
·
May 14

Senti Biosciences Holdings Inc - Senti-202 Future Manufacturing to Use Donor X Phenotype

THOMSON REUTERS
·
May 14

Senti Biosciences deregisters common stock under Exchange Act Form 15

Reuters
·
May 09

Senti Biosciences Inc - Enters Agreement to Issue up to $40 Mln in Senior Secured Convertible Notes - SEC Filing

THOMSON REUTERS
·
May 02

Senti Biosciences signs securities purchase deal for up to $40 million convertible notes

Reuters
·
May 02

Senti Bio CEO Timothy Lu to present logic-gated NK cell therapy at AACR meeting

Reuters
·
Apr 13

BRIEF-Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing

Reuters
·
Apr 02

Senti Biosciences plans tax-free holding company reorganization by April 16

Reuters
·
Apr 02

Senti Bio study in Cell Systems advances NOT-gated CAR design for T and NK therapies

Reuters
·
Apr 01

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 30

Chardan Cuts Price Target on Senti Biosciences to $11 From $13, Keeps Buy Rating

MT Newswires Live
·
Mar 30